Skip to main content
Article thumbnail
Location of Repository

Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of Warfarin

By Kirsten Neudoerffer Kangelaris, Stephen Bent, Robert L. Nussbaum, David A. Garcia and Jeffrey A. Tice
Topics: Clinical Review
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:2669873
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2000). A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy. Thromb Haemost.
    2. (1993). A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost.
    3. (2007). A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther.
    4. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.
    5. (2005). A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res.
    6. (2008). A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med.
    7. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
    8. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.
    9. Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane.
    10. (2001). Assessing impact of organizational interventions — Marshfield Clinic’s Coumadin Clinic Evaluation: Final Report.:
    11. (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials.
    12. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
    13. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
    14. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.
    15. Bias in metaanalysis detected by a simple, graphical test.
    16. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.
    17. (2006). Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost.
    18. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.
    19. CReating an Optimal Warfarin Nomogram (CROWN) Trial.
    20. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.
    21. CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study. Clin Pharmacol Ther.
    22. CYP2C9*3 allelic variant and bleeding complications.
    23. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.
    24. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data.
    25. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
    26. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra— and interpopulation differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics.
    27. Direct-to-consumer genetic testing: access and marketing.
    28. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
    29. (2009). Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data: The International Warfarin Pharmacogenetics Consortium.
    30. (2007). Estimation of warfarin m a i n t e n a n c ed o s eb a s e do nV
    31. (2007). Evaluation of genetic factors for warfarin dose prediction. Clin Med Res.
    32. (2009). FDA Approves Updated Warfarin (Coumadin) Prescribing Information: New GeneticInformationMay HelpProvidersImproveInitialDosingEstimatesof the Anticoagulant for Individual Patients. http://www.fda.gov/bbs/topics/ NEWS/2007/NEW01684.html. Accessed
    33. Genetic determinants of response to warfarin during initial anticoagulation.
    34. Genetic-based dosing in orthopedic patients beginning warfarin therapy.
    35. (2006). Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis.
    36. (1997). Human P450 metabolism of warfarin. Pharmacol Ther.
    37. (2006). Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther.
    38. (2008). Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and metaanalysis.
    39. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
    40. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.
    41. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy.
    42. Managing oral anticoagulant therapy.
    43. Measuring inconsistency in meta-analyses.
    44. (1986). Meta-analysis in clinical trials. Control Clin Trials.
    45. (2000). Methods for Metaanalysis in Medical Research: Assessing Between Study Heterogeneity.
    46. of Cardiology Foundation guide to warfarin therapy.
    47. Operating characteristics of a rank correlation test for publication bias.
    48. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.
    49. (2001). Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet.
    50. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost.
    51. (2002). Quantifying heterogeneity in a metaanalysis. Stat Med.
    52. (2007). Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation.
    53. (2009). Regulatory Perspective on Warfarin Relabeling with Genetic Information.
    54. (2008). Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.
    55. (1993). Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med.
    56. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
    57. (2005). Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther.
    58. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice.
    59. (2009). Test. http://www.kimballgenetics.com/pdf/Warfari nEdusheetv7.pdf. Accessed
    60. (2009). Test. http://www.nanosphere.us/VerigeneWarfarin MetabolismNucleicAcidTest_4472.aspx. Accessed
    61. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.
    62. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
    63. (2008). The largest prospective warfarintreated cohort supports genetic forecasting.
    64. The pharmacogenetics of coumarin therapy.
    65. (2008). Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther.
    66. (2004). Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost.
    67. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.
    68. (2007). WarfarindoseandthepharmacogenomicsofCYP2C9and VKORC1 - rationale and perspectives. Thromb Res.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.